Lung cancer trials in France

In France 316 Also abroad 2746

316 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Where
Avignon, Brest, Creteil Cedex, Lille, Lyon, Marseille, Montpellier Cedex 5, Nantes Cedex 2, Paris, Paris Cedex 20, Rennes Cedex 9, Saint-Herblain, Strasbourg Cedex, Toulon Cedex 9, Toulouse, Villejuif
Age
18 years and over
People
780 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Where
Bron, Grenoble Cedex 9, Paris, Saint-Herblain, Vandoeuvre Les Nancy
Age
18 years and over
People
182 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06855771 · EU 2024-519814-29-00
No phaseNot yet taking people in France
Short- and Mid-term Therapeutic, Prognostic, and Societal Impact of Implementing Intraoperative Assessment of Pulmonary Resection Quality for Lung Cancer
Where
Angers, Bobigny, Bordeaux, Clermont-Ferrand, Dijon, Le Plessis-Robinson, Lille, Lyon, Marseille, Nantes, Paris, Poitiers, Rennes, Rouen, Strasbourg, Suresnes, Toulouse, Tours
Age
18 years and over
People
2,400
Run by
Fondation Hôpital Saint-Joseph
See details and how to joinNCT07828938
Phase 1/2Taking people
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Where
Nice, Paris, Suresnes
Age
18 years and over
People
118 worldwide
Run by
MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07407933
Phase 1/2Taking people
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Where
Clichy, Nantes, Villejuif
Age
18 years and over
People
630 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06427941 · EU 2025-524136-19-00
Phase 1Taking people
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
Where
Lyon, Marseille, Toulouse, Vandoeuvre Les Nancy Cedex
Age
18 years and over
People
62 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521702-18-00
Phase 4Not yet taking people in France
Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.
Where
Nice Cedex 2
Age
18 years and over
People
110
Run by
Centre Antoine Lacassagne
See details and how to joinNCT07633613 · EU 2026-526866-26-00
Phase 3Taking people
Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
Where
Besancon Cedex, Lyon Cedex 04, Marseille, Rennes Cedex 9, Saint-Herblain, Toulouse
Age
18 years and over
People
168 worldwide
Run by
Amgen Inc.
See details and how to join2026-525489-23-00
No phaseTaking people
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Where
Besançon, Levallois-Perret, Marseille, Neuilly, Paris
Age
18 years and over
People
2,285 worldwide
Run by
Guardant Health, Inc.
See details and how to joinNCT05059444
No phaseTaking people
Lung cAncer Robotic Comparative Study
Where
Marseille, Rouen, Toulouse
Age
18 years and over
People
600 worldwide
Run by
Intuitive Surgical
See details and how to joinNCT06038227
Phase 1/2Taking people
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Where
Paris, Villejuif
Age
18 years and over
People
250 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06657222 · EU 2025-522517-35-00
No phaseTaking people
Virus-associated Tumour Microenvironment
Where
Paris
Age
18 years to 100 years
People
150
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT06471296
Phase 1Taking people
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Where
Dijon, Saint-Herblain, Toulouse
Age
18 years and over
People
383 worldwide
Run by
Iambic Therapeutics, Inc
See details and how to joinNCT06253871
Phase 2Taking people
Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
Where
Bordeaux, Nice, Villejuif
Age
18 years and over
People
40
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07016230
Phase 4Not yet taking people in France
Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy_POG
Where
Bron, Caluire-et-Cuire, Chevilly-Larue, Dijon, Lille Cedex, Lyon Cedex 04, Marseille, Paris, PARIS, Paris Cedex 20, Pierre-Bénite, Rennes Cedex, Saint-Cloud, Strasbourg Cedex 2, Toulouse, Villejuif
Age
65 years and over
People
794
Run by
Institut Gustave Roussy
See details and how to join2025-523610-83-00
Phase 3Taking people
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Where
Besancon Cedex, Bordeaux, Brest, Dijon, Lyon, Marseille, Montpellier Cedex 5, Rennes Cedex, Rouen Cedex, St Herblain, Strasbourg, Toulouse Cedex 9, Tours Cedex 9, Villejuif
Age
18 years and over
People
87 worldwide
Run by
Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00
No phaseTaking people
PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in NSCLC
Where
Angers, Le Mans
Age
18 years and over
People
75
Run by
University Hospital, Angers
See details and how to joinNCT06195527
Phase 4Not yet taking people in France
Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.
Where
Villejuif
Age
70 years and over
People
794
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07802847
Phase 2Taking people
FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and platinum as first line treatment in patients with large-cell neuroendocrine carcinomas (LCNECs) of the lung.
Where
Aix En Provence, Amiens Cedex 1, Brest Cedex 2, Caen Cedex 5, Créteil, Grenoble Cedex 9, Lille, Limoges Cedex 1, Lorient, Lyon, Lyon Cedex 02, Marseille, Meaux, Mulhouse, Nice, Paris, Paris Cedex 20, Pringy Cedex, Quimper Cedex, Rennes, Strasbourg, Strasbourg Cedex, Toulon Cedex 9, Villefranche Sur Saone Cedex
Age
18 years and over
People
80
Run by
Centre Leon Berard
See details and how to join2023-506590-35-00
Phase 1Taking people
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Where
Bordeaux, Caen, Lille, Lyon, Marseille, Nantes, Nice, Paris, Pierre-Bénite, Poitiers, Toulouse, Villejuif
Age
18 years and over
People
400 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT04913285
Phase 1/2Taking people
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
Where
Bordeaux, Lyon, Marseille Cedex 5, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
171 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT06567015 · EU 2023-510203-21-00
No phaseNot yet taking people in France
Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance
Where
Créteil, Lyon
Age
18 years and over
People
2,000 worldwide
Run by
Mark C Burgmans, MD PhD
See details and how to joinNCT07636148
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Angers, Bron, Creteil Cedex, Grenoble Cedex 9, Lyon Cedex 04, Marseille, Paris, Pessac, Pierre-Bénite, Rennes Cedex 9, Saint-Herblain, Strasbourg, Villejuif
Age
18 years and over
People
355 worldwide
Run by
Gilead Sciences Inc.
See details and how to join2024-515884-69-00
Phase 2Taking people
LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor
Where
Bordeaux, Clermont-Ferrand, Marseille, Montpellier Cedex 5, Vandoeuvre Les Nancy
Age
18 years and over
People
36 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04939610 · EU 2023-508995-12-01
Phase 1/2Taking people
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Where
Bordeaux, Saint-Herblain Cedex
Age
18 years to 100 years
People
280 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00